Posted: June 9th, 2022
Barco N.V. v. Sahara Presentation Systems PLC, District Cout The Hague, 1 June 2022, Case No. HA ZA 19-503 Barco holds EP ‘668 for an ‘Electronic tool and methods for meetings’and markets a presentation system under de name ‘ClickShare’ that incorporates the EP ‘668 technology. ClickShare enables participants to a meeting to share images and […]
READ MOREPosted: June 2nd, 2022
The Italian Supreme Court on patent infringement by equivalents: central relevance must be given to the individual elements claimed by the patent By judgment no. 120 on 4th January 2022, the Italian Supreme Court addressed the topic of patent infringement by equivalents. In particular, the Court provided guidance on two debated issues under Italian law: […]
READ MOREPosted: May 19th, 2022
Bristol-Myers Squibb Holdings Ireland Unlimited Company v. Sandoz B.V., District Court The Hague (interlocutory decision), 10 May 2022, Case no. ECLI:NL:RBDHA:2022:4385 BMS markets the medicine Eliquis®, with apixaban as the active ingredient. Apixaban is a substance that inhibits the action of factor Xa. Inhibiting factor Xa helps prevent blood clots from forming. Eliquis® is used […]
READ MOREPosted: May 5th, 2022
Novartis Pharma vs. Medac Farma, Court of Milan, 10 January 2022, Case number 11933/2022 A decision on second medical use patent and skinny labelling in Italy was handed down by the Court of Milan on 10 January 2022. The Court held skinny label alone as insufficient to avoid infringement of second medical use claims and […]
READ MOREPosted: April 29th, 2022
Preliminary ruling under Article 267 TFEU in the case between Phoenix Contact GmbH & Co. KG v. HARTING Deutschland GmbH & Co. KG, Harting Electric GmbH & Co. KG, 28 April 2022, Case No. C‑44/21, ECLI:EU:C:2022:309 “By its question, the referring court asks, in essence, whether Article 9(1) of Directive 2004/48 must be interpreted as […]
READ MOREPosted: April 20th, 2022
Novartis versus Mylan, PI judge District Court of The Hague 22 March 2022, ECLI:NL:RBDHA:2022:2490 (interlocutory decision) Market entry by the generic pharmaceutical company Mylan before the grant of a Novartis patent – which will be infringed once granted – is not unlawful. Not even if Novartis’ patent will be granted with certainty and the wording […]
READ MOREPosted: April 13th, 2022
Shark Helmets S.A.S. v. Tech Design Team S.L., Commercial Court no. 5 of Barcelona, 28 October 2021, Docket No. 729/2020 In this decision issued on 28 October 2021, Barcelona first instance Patent Courts examined the question of interpreting the extent of protection of the claims in view of the patent description and drawings. The plaintiff, […]
READ MOREPosted: March 30th, 2022
Judgment handed down in the last of the technical trials in Optis v Apple saga: Optis succeeds in arguing that its patents are valid and infringed by Apple Overview The 15 March 2022 judgment of Mr Justice Meade is the latest in the Optis v Apple saga. It is the last in the series of […]
READ MOREPosted: March 29th, 2022
Vorwerk v. Lidl Supermercados, Court of Appeals of Barcelona, Spain, 13 January 2022, Appeal Docket No. 880/2021 (ECLI:ES:APB:2022:1) One year after the first-instance ruling in one of the most mediatic patent cases in Spain, the Court of Appeals of Barcelona rendered a judgment changing course, namely inreversing the first instance judgment and declaring the invalidity […]
READ MORE
EMAIL US
